Equal male and female incidence of myasthenia gravis

Poulas, Konstantinos; Tsibri, E.; Papanastasiou, D.; Tsouloufis, T.; Marinou, Martha; Tsantili, Panayota; Papapetropoulos, T; Tzartos, Socrates J.

doi:10.1212/wnl.54.5.1202

Cited by 16 publications

(14 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The data presented in this study agree with our previous report,25 which stated that the incidence in men and women is equal. We had estimated that, with a women:men incidence ratio of 1:1, the prevalence ratio would be 1.74:1, as women patients with myasthenia gravis have a much longer average life expectancy and disease duration after onset (women:men myasthenia gravis life expectancy=40:23 years or 1.74:1) 25.…”

Section: Discussionsupporting

confidence: 93%

“…We had estimated that, with a women:men incidence ratio of 1:1, the prevalence ratio would be 1.74:1, as women patients with myasthenia gravis have a much longer average life expectancy and disease duration after onset (women:men myasthenia gravis life expectancy=40:23 years or 1.74:1) 25. In this study, we found a women:men prevalence ratio of 1.41:1.…”

Section: Discussionmentioning

confidence: 47%

See 1 more Smart Citation

Epidemiology of seropositive myasthenia gravis in Greece

Poulas

2001

Journal of Neurology, Neurosurgery &Amp; Psychiatry

View full text Add to dashboard Cite

Objectives-To study the epidemiological characteristics of myasthenia gravis in Greece. Methods-A population based study was carried out of seropositive myasthenia gravis in Greece for the period from 1 January 1983 to 30 June 1997; 843 patients were studied. Results-The average annual incidence for the period 1992-7, for which the database is complete, was 7.40/million population/year (women 7.14; men 7.66). On 1 July 1997, there were 740 prevalent cases. The point prevalence rate was 70.63/million (women 81.58; men 59.39). The average overall annual mortality rate in the patients was 0.67/million population (women 0.53; men 0.82), and the mortality rate attributed to myasthenia gravis was 0.43/million population (women 0.41; men 0.45). The average age at onset was 46.50 years (women 40.16; men 54.46), and the mean age of the prevalent patients was 52.58 (women 47.65; men 59.48). The women:men incidence ratio was 1:1.04, and the prevalence ratio was 1.41:1. It is predicted that the prevalence and women: men prevalence ratio would increase if the patient list included all patients with a date of onset before 1983. Conclusions-The largest epidemiological study ever performed on myasthenia gravis is presented. The most important epidemiological indexes are provided. (J Neurol Neurosurg Psychiatry 2001;71:352-356)

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 47%

Epidemiology of seropositive myasthenia gravis in Greece

Poulas

2001

Journal of Neurology, Neurosurgery &Amp; Psychiatry

View full text Add to dashboard Cite

show abstract

“…To clarify whether the generally accepted 2:1 female-tomale ratio in MG prevalence is also valid for disease incidence, Poulas et al [5] analyzed 601 seropositive patients with disease onset between 1983 and 1998 in Greece. The incidence ratio was 1:1, and it was concluded that MG affects men and women equally, despite the unequal prevalence [5].…”

Section: Current Trends In the Epidemiology Of Myasthenia Gravismentioning

confidence: 99%

“…The incidence ratio was 1:1, and it was concluded that MG affects men and women equally, despite the unequal prevalence [5].…”

Section: Current Trends In the Epidemiology Of Myasthenia Gravismentioning

confidence: 99%

Advances in myasthenia gravis

Ciafaloni

Sanders

2002

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

Recent advances in the diagnosis and treatment of acquired myasthenia gravis (MG) are reviewed. Increased awareness about the need for more uniform methods of reporting treatment trials for MG has prompted systematic review of the literature and inspired an effort to develop better classifications and disease-specific outcome measures. New antibodies have been discovered in patients with seronegative MG, possibly defining an immunologically distinct form of the disease. A new immunosuppressant, mycophenolate mofetil, may be an additional and safe option in the treatment of MG. Other work supports the possibility of developing a vaccine against MG suitable for trial in humans.

show abstract

“…

age-related patterns [4][5][6] , the gender difference in MG frequency and its age-related behavior is still debated [7] . We designed a population-based incidence study in the province of Ferrara, over the 16-year period 1985 through 2000, to estimate the incidence of the disease and to examine the gender disparity in a community setting.

Materials and Methods

The province of Ferrara lies in the Emilia-Romagna region, northeastern Italy.

…”

mentioning

confidence: 99%

Incidence of Myasthenia gravis in the Province of Ferrara

et al. 2004

View full text Add to dashboard Cite

Background: The reported annual incidence of myasthenia gravis (MG) ranges from 0.25 to 15 per million. The sex- and age-related pattern of disease incidence is still debated. Methods: An intensive descriptive study was performed in the province of Ferrara (mean population 360,950 people) over the period 1985 through 2000. Results: The average crude annual incidence rate was 2 per 100,000. We confirm a female preponderance in the total population, particularly in the youngest age groups. Conclusions: We observed an early increase in incidence in females, partly due to thymoma-associated MG, while MG without thymoma showed increasing incidence with age nonsignificantly different in the two sexes.

show abstract

Equal male and female incidence of myasthenia gravis

Cited by 16 publications

References 5 publications

Epidemiology of seropositive myasthenia gravis in Greece

Epidemiology of seropositive myasthenia gravis in Greece

Advances in myasthenia gravis

Incidence of Myasthenia gravis in the Province of Ferrara

Contact Info

Product

Resources

About